Home Tags Enhertu

Tag: Enhertu

US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC

The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...

Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...

The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...
Daiichi Sankyo

FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...

The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...

Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...

World ADC London 2022: What to Expect

With World ADC London staring later this week, excitement is building for the first in-person event in two years, with virtual attendance options available! With 70+ speakers...
ESMO 2017 - 3

Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer...

The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Remegen’s Disitamab Vedotin Attracts China’s largest-ever out-license Agreement at US $...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...

First patient Dosed with Trastuzumab Deruxtecan in DESTINY-Breast09 Head-to-Head HER2+ mBC...

A first patient was dosed in DESTINY-Breast09 (NCT04784715), a global head-to-head Phase 3 clinical trial evaluating the safety and efficacy of trastuzumab deruxtecan (Enhertu®;...

Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs

With the launch of fam-trastuzumab-deruxtecan-nxki (Enhertu®), Daiichi Sankyo's first antibody-drug conjugates, coupled with a strong pipeline of innovative ADC, the company has established a...

Daiichi Sankyo: Realigning for Agility

Daiichi Sankyo first approached me in 2015 with a potential opportunity in global oncology development, and I listened carefully as they explained how they...

X